Listen

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Changing Therapeutic Landscape and the Role of the Pharmacist

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated, rare disorder leading to muscle weakness and sensory disturbance. It can be debilitating and lead to impaired mobility, difficulty or inability to perform activities of daily living, and severe disability. Conventional therapies are beneficial for patients with CIDP, but there are limitations associated with these therapies requiring consideration of the individual needs of the patient. New and emerging therapies including FcRn antagonists provide targeted therapies, and pharmacists must be aware of the current clinical evidence, appropriate patient selection, identifying where these agents fit within the current treatment algorithm, and methods to transition patients to these therapies to provide individualized, patient-centered care and improve patient outcomes.

This educational activity will discuss the pathophysiology of CIDP as well as the incidence, prevalence, clinical course, and burden of disease. A review of the current guideline-recommended therapies will be discussed, including any treatment limitations. The most recent clinical evidence of new and emerging therapies in CIDP will be explored and opportunities for pharmacists to improve patient care through optimizing therapy, medication monitoring, providing access to medications, patient education, promoting adherence, care coordination, and adjunct care including recommending appropriate vaccinations.

Wednesday, Dec. 8
11:30 a.m. - 1 p.m. PT (2:30 - 4 p.m. ET)

Islander Ballroom H, Lower Level, Mandalay Bay North Convention Center

Come early! Seating is limited and provided on a first-come, first-served basis.

Can't make it to Las Vegas? Tune into the Free Live Webinar Broadcast.
Registration is required for the webinar.

Webinar Registration

Speakers

Claire Spahn, PharmD, MS, BCPS Activity Chair
Clinical Pharmacist, Department of Pharmacy
Stanford Health Care
Stanford, California

Claire Spahn is a clinical pharmacist at Stanford Health Care in Stanford, California. Dr. Spahn received her BS(Pharm degree from Trinity College, Dublin, Ireland, her PharmD degree from Western University of Health Sciences in Los Angeles and an MS degree from University of Florida. She completed a PGY1 acute care pharmacy residency at Stanford Health Care, Stanford California. Dr. Spahn practices in specialty ambulatory care clinics including neurology and pharmacogenomics.

Neelam Goyal, MD
Clinical Professor, Department of Neurology and Neurological Sciences, Division of Neuromuscular Medicine
Stanford University
Palo Alto, California

Neelam Goyal is a Clinical Professor of Neurology and Neurological Sciences in the division of Neuromuscular Medicine. She earned her medical degree at SUNY Downstate in Brooklyn, NY. Subsequently, she completed her neurology residency, which included a chief year, followed by a fellowship year in neurophysiology, specializing in neuromuscular disorders and EMG nerve conduction studies at Stanford University Medical Hospital. Dr. Goyal focuses on the diagnosis, management, and electrophysiological testing of neuromuscular disorders, including SFEMG. Her expertise extends to immune-mediated disorders such as myositis, myasthenia gravis, CIDP, and vasculitis. Her research interests involve monitoring and managing the short and long-term toxicity of immunosuppressive agents. She is actively involved in a grant-supported project investigating steroid toxicity in patients with myasthenia gravis.

Target Audience

This 1.5 hour educational activity was planned to meet the educational needs of pharmacists who practice in hospitals, health systems, specialty pharmacies, and ambulatory clinics who care for or are interested in the care of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Learning Objectives

Describe the pathophysiology, prevalence/incidence, burden of illness, and identification of patients with CIDP.
Evaluate treatment guidelines and conventional therapies for CIDP.
Analyze evidence of new and emerging treatments for CIDP including their mechanism of action, pharmacology, current clinical trial data including safety and efficacy, and where these agents may fit into practice.
Apply evidence-based approaches to individualize patient-centered treatment and counseling to improve patient safety, adherence, access, and outcomes.

Agenda

11:30 a.m. – Welcome and Introductions
Claire Spahn
11:35 a.m. – Overview of CIDP
Claire Spahn
11:50 a.m. – Guideline-recommended Therapy Options for CIDP
Claire Spahn
12:10 p.m. – New and Emerging Therapies for CIDP
Neelam Goyal
12:30 p.m. – The Role of the Pharmacist: Approaches to Individualizing and Optimizing Therapy
Claire Spahn
12:50 p.m. – Faculty Discussion, Questions and Answers
All Faculty

Accredited for CPE

ACPE #: 0204-0000-25-414-L01-P
CE Credit: 1.5 contact hours (0.15 CEUs)
Activity Type: Application-based
Activity Fee: No charge

To Claim CE for the webinar, enter the CE code announced during the activity and complete the evaluation.